Amarakoon S, Martinez-Ciriano JP, Baarsma S, et al. - In this prospective, single-centre clinical trial involving 191 patients with exudative age-related macular degeneration (ARMD), researchers sought to determine choroidal neovascularization (CNV) recurrence rates after anti-VEGF treatment is discontinued. Participants in the study were assigned randomly to receive intravitreal bevacizumab injections every 4, 6, or 8 weeks for one year. In the 157 patients who completed the one-year treatment regimen, CNV activity was determined. Sixty-six (42%) of the 157 patients still had signs of persistent active CNV after one year of treatment. Anti-VEGF therapy was discontinued in 58% of patients after receiving bevacizumab injections every 4, 6, or 8 weeks for one year based on quiescent disease; 67% showed reactivated CNV within the year following discontinuation. The high CNV reactivation rate shown in this study could assist clinicians to establish protocols for rational discontinuation.